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Abstract
Background:  Obstructive sleep apnea syndrome (OSAS) is a recognized risk factor for
cardiovascular morbidity and mortality, perhaps due to causative exacerbations of systemic
oxidative stress. Putative oxidative stress related to numerous episodes of intermittent hypoxia,
may be an oxidants chief driving force in OSAS patients.
Methods: We assessed the resting and n-formyl-methionyl-leucyl-phenylalanine (fMLP)- induced
whole blood chemiluminescence (as a measure of oxidant production by polymorphonuclear
leukocytes and monocytes), ferric reducing ability of plasma (FRAP) and H2O2 generation in the
whole blood of 27 untreated OSAS patients, 22 subjects after a night of CPAP therapy and 11
controls without OSAS. All of them were matched to age, BMI (body mass index) and smoking
habits. All parameters were measured before and after polysomnography-controlled sleep,
individual results were obtained as a mean from duplicated experiments.
Results:  No significant differences were distinguished between evening and morning blood
chemiluminescence, H2O2 activity and FRAP within and between all three study groups.
For instance patients with untreated OSAS had similar morning and evening resting whole blood
chemiluminescence (2.3 +/- 2.2 vs. 2.4 +/- 2.2 [aU·10-4 phagocytes]), total light emission after
stimulation with fMLP (1790 +/- 1371 vs. 1939 +/- 1532 [aU·s·10-4 phagocytes]), as well as FRAP
after 3 min. plasma incubation (602 +/- 202 vs. 671 +/- 221 [uM]). Although, in the subgroup of 11
patients with severe OSAS (apnea/hypopnea index 58 +/- 18/h and oxygen desaturation index 55
+/- 19/h), the morning vs. evening resting chemiluminescence and total light emission after
stimulation with fMLP observed a propensity to elevate 2.5 +/- 2.7 vs. 1.9 +/- 1.8 [aU·10-4
phagocytes] and 1778 +/- 1442 vs. 1503 +/- 1391 [aU·s·10-4 phagocytes], respectively, these did not
attain statistical significance (p > 0.05).
Conclusion:  Our investigation exposed no evidence in the overproduction of oxidants via
circulating phagocytes, once considered a culprit in the oxidative stress of OSAS patients.
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Background
The presence of obstructive sleep apnea syndrome (OSAS)
is strongly associated with augmented morbidity and
mortality from cardiovascular diseases including arterial
hypertension, cardiac arrhythmias and ischemic heart dis-
ease [1,2]. OSAS is also considered to be a risk factor of
stroke and sudden cardiac death [3,4]. There appears to be
practicable links between OSAS and occurrences such as
apnea-induced intermittent hypoxia (IH) of tissues, sym-
pathetic over activities during sleep [5,6] as well as puta-
tive oxidative stress in relation to the systemic
inflammatory response [6,7]. Primed and or activated cir-
culating polymorphonuclear leukocytes (PMNs) and
monocytes can be a source of reactive oxygen species
(ROS) in OSAS patients [7]. Indeed, the in vitro incuba-
tion of whole blood under decreased partial oxygen pres-
sure (pO2 ≤ 46 mm Hg) resulted in the degranulation of
PMNs [8] and increased ROS production [9].
Moreover, healthy volunteers subjected to 20 min hypo-
baric hypoxia in a decompression chamber presented
with elevated production of ROS by PMNs [10].
Due to repeated apnea and/or hypopnea episodes, noctur-
nal PaO2 can fall below 50 mmHg in OSAS patients
[11,12] and thus favor activation and enhance ROS pro-
duction by means of blood phagocytes. Scanty and con-
flicting data concerning ROS production by blood
phagocytes in the course of OSAS have been published so
far [13-16]. Müns et al. did not establish any alterations in
ROS production accompanying ingestion of Escherichia
coli by PMNs obtained from OSAS patients [13]. Other
researchers have illustrated that increasing the agonist n-
formyl-methionyl-leucyl-phenylalanine (fMLP), induced
production of superoxide radicals in isolated PMNs from
OSAS patients [14]. However, the limitation of that study
attributes to the control groups' significant difference in
respect to age, body mass index (BMI) as well as habitual
cigarette smoking. In addition, the control group included
cancer patients and healthy subjects not matched to OSAS
patients with comorbidity [14]. In another study Dyugov-
skaya et al. [15] identified subpopulations of monocytes
and PMNs in OSAS patients (using the flow cytometry
technique) producing more ROS than the cells from the
control group. Yet, in this study, the control group also
differed with regard to BMI, comorbidity and concomi-
tant pharmacological treatment. On the other hand, the
significant suppression of fMLP- induced respiratory burst
of isolated PMNs was reported in patients with severe
OSAS using the chemiluminescence technique [16-18].
Taking into account the divergences between these stud-
ies, we decided to monitor ROS production by PMNs and
monocytes in both untreated- and CPAP-treated OSAS
patients and age-, BMI- and cigarette-smoking habit-
matched controls (volunteers without OSAS). Two addi-
tional variables reflecting oxidant/antioxidant imbalances
were determined: the H2O2 activity in the whole blood
[19] and the ferric reducing ability of plasma (FRAP) [20].
We found that the apnea/hypopnea episodes during sleep
did not change the morning and evening intensity of the
resting as well as fMLP-induced LBCL, FRAP and blood
H2O2 activities in the OSAS patients. These suggest a lack
of apparent ROS overproduction via circulating PMNs in
OSAS patients.
Methods
Chemicals and solutions
Luminol, horseradish peroxidase (HRP, 222 I.U./mg),
2,4,6-tripyridyl-s-triazine (TPTZ), bovine catalase (2440
I.U./mg of solid substance), n-formyl-methionyl-leucyl-
phenylalanine (fMLP), FeCl3·6H2O and dimethyl sul-
phoxide (DMSO) were obtained from Sigma Chemical
Co. (St. Louis, MO, USA). Phenol red and phosphate buff-
ered saline (PBS, pH 7.4) came from ICN Biomedicals Inc
(Aurora, OH, USA) and Biomed (Lublin, Poland). All
other reagents were of analytical grade and were pur-
chased from the POCH (Gliwice, Poland). Stock solutions
of 1.4 M luminol in 0.1 M phosphate buffer (pH 7.4), 20
mM fMLP in DMSO, catalase in 0.9% NaCl (50 I.U/μl)
and HRP in 50 mM phosphate buffer (0.925 I.U/μl, pH
7.0), 10 mM TPTZ in 40 mM HCl, and 0.028 M phenol
red in water were stored in single use aliquots in the dark
at -70°C. fMLP was diluted just before use with 0.9%
NaCl to a final concentration 0.2 mM. Sterile, deionized,
pyrogen-free water for HPLC (resistance > 18 Ωcm, Water
Purification System USF ELGA, Buckinghamshire, UK)
was used throughout the study.
Study population and polysomnography
Sixty patients that underwent polysomnography at the
Sleep Laboratory were studied. Thirty-eight patients
underwent diagnostic polysomonography following a
preliminary diagnosis of OSAS. The remaining 22, previ-
ously diagnosed with OSAS met indication for continuous
positive airway pressure (CPAP) treatment.
The inclusion criteria incorporated an age span from 40 to
70 years along with a written informed consent. The
exclusion criteria involved pregnancy, presence of any
active infectious or inflammatory process, chronic
obstructive pulmonary disease (COPD), unstable angina,
uncontrolled hypertension or hypertension diagnosed
within the last three months, insulin-dependent diabetes,
and any surgery within the last three months, or treatment
with antibiotics, nonsteriodal anti-inflammatory drugs,
vitamins as well as any food supplements with antioxi-
dant potential within the preceding two weeks. All partic-
ipants, except for patients treated with CPAP, underwent
a standard overnight (7 hours from about 11:00 pm to
6:00 am) polysomnography (SleepLabPro, Jaeger, VIASYSJournal of Negative Results in BioMedicine 2008, 7:10 http://www.jnrbm.com/content/7/1/10
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Healthcare Hoechberg, Germany). This entailed an EEG,
electrooculography, chin muscles as well as an anterior
tibial electromyography (EMG), a unipolar EKG, snoring
detection, body position, measurement of oronasal air-
flow along with abdominal and chest respiratory move-
ments as previously described [21]. Participants
previously diagnosed with OSAS, underwent a similar
standard polysomnography trial CPAP treatment (CPAP
Respironics, RemStar Plus, Murrysville, Pennsylvania,
USA) along with a mask pressure monitoring as a substi-
tute in measurement of oronasal flow. The polysomnog-
raphy enabled differentiation in two groups of patients-
the OSAS group – 27 patients with OSAS (apnea/hypop-
nea index, AHI>5) including the subgroup of 11 patients
with severe OSAS (AHI ≥ 30), from patients without OSAS
(AHI<5) who served as a control group (n = 11). The third
group (CPAP-OSAS group) involved OSAS patients (n =
22), successful at the first attempt of CPAP treatment
(Table 1, 2, and 3).
Study Design
All participants were admitted to the Sleep Laboratory at
approximately 8:30 p.m., previously instructed to con-
sume a light final meal before 7:00 p.m. Venous blood
was collected twice for blood cell count and measurement
of oxidative stress markers – before and after polysomnog-
raphy-controlled sleep, at about 9:30 p.m. and 6:00 a.m.
(just after wakening up), respectively. Nine ml of venous
blood were drawn into sodium heparin vacuette tubes
(placed in ice-cold water) and EDTA-K3 vacuette-tubes
(Greiner bio-one GmbH, Kremsmunster, Austria). The
heparinized blood was used for measuring whole blood
Table 1: Demographics of investigated groups
Subjects that underwent polysomnography
Parameter OSAS group, n = 27 Severe OSAS subgroup, n = 11 CPAP-OSAS group, n= 22 Controls, n = 11
Male/Female 25/2 10/1 17/5 9/3
Smokers 15 0 15 6
Age [yrs] 53 ± 13 55 ± 15 58 ± 8 50 ± 10
BMI [kg/m2] 31.1 ± 5.1 32.1 ± 6.5 34.3 ± 7.3 28.8 ± 5.5
NC [cm] 42.6 ± 2.6 43.7 ± 2.9 43.7 ± 4.1 41.5 ± 2.0
ESS 11 ± 1 11 ± 5 15 ± 1* 9 ± 1
TST [h] 4.8 ± 1.2 4.7 ± 1.3 5.2 ± 1.6 5.3 ± 1.0
AHI [n/h] 31 ± 5 58 ± 18 † 9 ± 2* 2 ± 1*
ODI [n/h] 31 ± 5 55 ± 19 † 9 ± 3* 2 ± 1*
Mean SaO2 [%] 87 ± 1 84 ± 5 † 89 ± 1 91 ± 1*
Min SaO2 [%] 74 ± 3 68 ± 15 † 81 ± 2 88 ± 1*
TSaO2<88% [min] 55 ± 12 99 ± 74 † 12 ± 4* 2 ± 1*
Snoring [%TST] 29 ± 24 28 ± 24 10 ± 14* 20 ± 25
OSAS – patients with untreated OSAS; Severe OSAS – patients with AHI ≥ 30; CPAP-OSAS – patients with OSAS treated successfully at a first 
attempt with CPAP, controls – subjects without OSAS; BMI – body mass index; NC – neck circumference; ESS – Epworth sleepiness score; TST – 
total sleep time; AHI (apnea/hypopnea index) – the number of apneas and hypopneas per hour of sleep; ODI (oxygen desaturation index) – the 
number of desaturations ≥ 4% per hour of sleep; SaO2-nocturnal oxygen saturation; TSaO2 – duration of nocturnal oxygen saturation < 88%. 
Polysomnography data expressed as a mean ± SD. The daily cigarette consumption was 19 ± 12, 21 ± 13, and 17 ± 6 for current cigarette smokers 
in OSAS, CPAP-OSAS and control groups respectively. Blood for chemiluminescence measurement and other determinations was taken before and 
after polysomnographic controlled sleep.
* – p < 0.05 vs. OSAS group, † – p < 0.05 vs. CPAP-OSAS and controls groups.
Selected baseline characteristics of CPAP-OSAS patients before treatment initiation were: AHI 58 ± 29; ODI 56 ± 26; mean SaO2 82 ± 7 %, min 
SaO2 75 ± 9 %, and TSaO2 < 88% 105 ± 90 min. of 5.2 ± 1.7 h TST.Journal of Negative Results in BioMedicine 2008, 7:10 http://www.jnrbm.com/content/7/1/10
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H2O2 activity, followed by its addition to other reagents
within 10 seconds from collection. Luminol enhanced
whole blood chemiluminescence (LBCL) measurement
procedure (EDTA-K3  blood samples with determined
blood cell count) began no later than 30 min. following
blood collection. Plasma samples obtained from EDTA-K3
blood (30 min incubation at 37°C, subsequent centrifu-
gation for 10 min at 1500·g and 4°C) were stored at -
70°C for no longer than 3 weeks until FRAP determina-
tion. Blood cell count was measured with Micros Analyzer
OT 45 (ABX, Montpellier, France). In the event of an at
night awakenings, only plain mineral water was allowed
to be drunk ad libitum. The Medical University of Lodz
Ethics Committee approved the study protocol and all
participants provided a written, informed consent.
Luminol enhanced whole blood chemiluminescence assay
A luminol enhanced whole blood chemiluminescence
(LBCL) technique was employed as a measure of resting
and agonist induced ROS production by circulating
phagocytes [17,18] in order to avoid any priming and/or
activation of oxidative cell response due to isolation pro-
cedures [18]. Moreover, to avoid any possible bias related
to patients' interindividual variability and differences in
comorbidity and pharmacological treatment, LBCL was
measured before (evening) and just after polysomnogra-
Table 2: Comorbidity in the investigated patient groups
Disease Number of patients with a given disease
OSAS n = 27 CPAP-OSAS n = 22 Controls n = 11
Arterial hypertension 16 16 4
Ischemic heart disease 7 7 2
Diabetes 2 4 0
Gout 0 4 0
OSAS – patients with untreated OSAS; CPAP-OSAS – patients with OSAS treated successfully after a first attempt with CPAP, controls – subjects 
without OSAS.
Table 3: Ongoing pharmacological treatment in studied groups
Pharmacological treatment Number of patients receiving treatment
OSAS, n = 27 CPAP-OSAS, n = 22 Controls, n = 11
ACEI 12 10 2
Diuretics 11 6 1
Ca2+ channel blocker 4 5 1
Beta-blockers 4 1 1
Nitrates 4 4 1
Digitalis 3 1 0
Statins 8 6 0
Allopurinol 0 4 0
Ticlopidine 2 0 1
Gliclazide 1 5 0
ACEI – angiotensin converting enzyme inhibitors; OSAS – patients with untreated OSAS; CPAP-OSAS – patients with OSAS treated successfully 
after a first attempt with CPAP, controls – subjects without OSAS. Four, 2, and 6 subjects were free of any medication in OSAS, CPAP-OSAS and 
controls group, respectively.Journal of Negative Results in BioMedicine 2008, 7:10 http://www.jnrbm.com/content/7/1/10
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phy-controlled sleep (morning) in a matched manner.
Therefore, evening results served as reference values
designed for morning data, presumably affected by
apnea/hypopnea episodes in addition to subsequent IH
during sleep.
LBCL as a measure of resting and fMLP-stimulated circu-
lating phagocytes (PMNs and monocytes) ability to pro-
duce ROS was determined according to Kukovetz et al.
[17] with some modifications [22]. Briefly, 3 μl of blood
sample was added to 947 μl of mixture solution (com-
posed of 1 ml sterile Ringer solution, 200 μl 5% D-glucose
solution, 3.6 ml deionized water and 5 ml 1.4 M luminol
solution) which was pre-warmed in darkness up to 37°C
for 60 min. The samples were placed in the 1251 lumi-
nometer (Bio-Orbit, Turku, Finland) and incubated for 30
min. at 37°C. Afterwards the resting chemiluminescence
was recorded continuously for 1 min. and then 50 μl fMLP
solution was added automatically to a final concentration
of 0.02 mM, with continuation of the light emission
measurement for an additional 7 min. All individual
results were obtained as a mean of four measurements
with LBCL parameters assessing resting chemilumines-
cence (rCl) – the average resting chemiluminescence prior
to the addition of fMLP; peak chemiluminescence (pCL)
– maximal chemiluminescence signal after the addition of
fMLP. Total light emission (tCL) – the area under the
chemiluminescence intensity curve after the addition of
fMLP until its return to baseline and peak time – the time
(seconds) from the addition of fMLP to the appearance of
pCL were also assessed. rCL and pCL were expressed in
arbitrary units (aU) per 104 phagocytes (PMNs and mono-
cytes) present in the assayed sample, while tCL in aU·s/
104  phagocytes. Preliminary experiments with platelet
rich plasma excluded the contribution of platelets to
fMLP-evoked LBCL (data not shown).
The H2O2 activity in the whole blood
H2O2 activity was measured in whole blood using the
phenol red oxidation method [19,23] with some modifi-
cations. Briefly, 600 μl of blood was either added to 60 μl
0.2 M NaN3 solution or 60 μl of bovine catalase solution
(3000 I.U. per sample) in 0.9% NaCl. Both tubes were
subsequently incubated for 5 min at 37°C and then a 30
μl 0.028 M solution of phenol red in deionized water with
a 30 μl (27.75 I.U. per sample) of HRP solution in 50 mM
phosphate buffer (pH = 7.0) were then added to each test-
tube. Afterwards, the samples were incubated for 10 min
at 37°C and then centrifuged (10 min., 1500·g). One
hundred μl of supernatant was transferred into a cuvette
containing 900 μl PBS and 10 μl 1 M NaOH reading
(spectrophotometer Ultrospec III, LKB Biochrom Eng-
land) its absorbance at 610 nm (A610). The calibration
curve was made with 600 μl samples of standard H2O2
solutions (increasing concentrations from 0.1 to 12 μM,
13 concentration points) in PBS added to 60 μl 0.2 M
NaN3 solution and subsequently processed in the same
way as blood specimens. The concentration of H2O2 (μM)
in the blood specimens was calculated according to the
regression equation: y = 33.12(x1-x2) – 0.23 (r = 0.97, p <
0.001) where y was the H2O2 concentration and x1-x2 was
the difference between the A610 of a sample with NaN3 (x1)
and A610 of a sample with catalase (x2) being the blank (all
H2O2 was decomposed by the enzyme). The method sen-
sitivity was 0.25 μM of H2O2. Individual results were
obtained as the mean of two measurements.
Ferric reducing ability of plasma
FRAP ascertainment was measured following the proce-
dure originally described by Benzie and Strain [20] with
some modifications [24], in which Fe3+ to Fe2+ ion reduc-
tion at low pH caused the formation of a coloured ferrous-
TPTZ complex, resulting in an increase in absorbance at
593 nm (A593). Briefly, 30 μl of plasma was mixed with 90
μl of deionized water and then added to 900 μl of a FRAP
reagent (pre-warmed to 37°C) while sample absorbance
at 593 nm was continuously measured over 8 min. at
37°C (Ultrospec III, with a Spectro-Kinetics software).
Control samples (blank) received 120 μl of water. FRAP
reagent was prepared just before the assay by adding in the
following order: 10 ml 300 mM acetate buffer (pH 3.6), 1
ml 10 mM TPTZ in 40 mM HCl, and 1 ml 20 mM aqueous
FeCl3 solution. Calibration was performed with a FRAP
reagent containing the addition of FeCl2 (total sample vol-
ume 1.02 ml, final concentrations from 20 to 2000 μM, 9
concentration points). Absorbance was linear (r = 0.98, p
< 0.001). Intra- and inter- assay coefficients of variations
tested on 10 aliquots of pooled plasma from 10 healthy
donors were less than 8%. Individual results were
obtained from duplicate experiments and were expressed
as a concentration of Fe3+ ions reduced into Fe2+ after 0, 1,
2, 3, 4, 5, 6, 7 and 8 min. incubation of plasma sample
with FRAP reagent. Calculations were done according to
the formula: Y [μM] = 1687.9 X – 3.3, where Y – concen-
tration of Fe3+ reduced ions, X – difference between A593
(assayed sample) and A593 (blank).
In vitro effect of H2O2 on FRAP
Nine hundred and fifty μl of pooled plasma samples
(obtained from 10 healthy donors) were mixed with 50 μl
of deionized water or 50 μl of various H2O2 solutions and
were incubated for 5, 30 and 60 min at 37°C. The final
concentration of H2O2 in plasma samples were 0 μM, 47
μM, 16.5 mM, and 82.5 mM, respectively. Then the sam-
ples were centrifuged (5 min., 1500·g, 4°C) and 30 μl of
plasma after mixing with 90 μl of water was added to 0.9
ml of FRAP reagent. A 593 was recorded over a 10 min.
incubation period at 37°C while the concentration of
reduced Fe3+ ions was calculated as above.Journal of Negative Results in BioMedicine 2008, 7:10 http://www.jnrbm.com/content/7/1/10
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Statistical analysis
All data were expressed, dependent on the distribution, as
the mean and standard deviation (SD) and/or median
and quartile range. Shapiro-Wilk W test was used for nor-
mality testing. The differences between groups (normal
data) were assessed using an analysis of variance for inde-
pendent variables. Repeated measures ANOVA was
applied for dependent variables (evening vs. morning).
For data not normally distributed, the Kruskal-Wallis test
and Friedman test were used. In the case of significance,
appropriate post-hoc tests were implicated. An additional
comparison between two selected parameters with an
abnormal distribution was conducted using the Wilcoxon
test (for dependent variables) and the U Mann-Whitney
test (for independent variables). The t-student test for
dependent variables was used in comparison of two nor-
mally distributed parameters. A p value of < 0.05 was con-
sidered significant. For differences between means, the
95% confidence intervals were calculated.
Results
White blood cells, phagocytes and hematocrit
In all three investigated groups, morning white blood cell
counts were lower as compared to the evening counts (p <
0.05). Evening and morning quantities of PMNs collec-
tively with monocytes differed significantly (p < 0.05).
Indistinguishable manifestations arose in the subgroup of
11 patients with severe OSAS (data not shown). This
explains why the LBCL was expressed per 104 phagocytes
despite the relatively diminutive time-interval between
evening and morning blood collections, in addition to the
data analysis of LBCL as a dependent variable. Conversely,
hematocrit was significantly unchanged (p > 0.05) (Table
4). Therefore, correction of plasma volume changes in
FRAP and H2O2 activities in the morning data was unnec-
essary.
Luminol enhanced whole blood chemiluminescence
No analyzed parameters of LBCL (rCL, pCL, tCL and peak-
time) altered significantly after sleep in patients with
OSAS and controls (Table 5). There were also no signifi-
cant differences between all three of the investigated
groups in respect to these parameters. Unpredictably, in
all groups, the tendency (although, insignificant) to
present a decreased LBCL (rCL, pCL and tCL) subsequent
to sleep was prominent.
Furthermore, patients with severe untreated OSAS (n =
11) did not reveal any differences between evening and
morning LBCL (p > 0.05). However, in the subgroup, the
observance of the reverse tendency to increase morning
LBCL parameters is notable (Table 5).
Ferric reducing ability of plasma
The 3 min. incubation of a plasma sample with a FRAP
reagent (containing Fe3+ and TPTZ) is recommended in
receiving the most reliable results in plasma antioxidant
activity [20]. Table 6 shows this data after 3 min. incuba-
tion with no significant differences noted between
evening and morning plasma FRAP within all of the ana-
lyzed groups. There were also no significant differences
between the corresponding values found in OSAS, CPAP-
Table 4: White blood cells, phagocytes and hematocrit
OSAS CPAP-OSAS CONTROLS
Hematocrit [%] Evening 39.2 ± 3.8 40.8 ± 4.8 37.4 ± 5.5
Morning 38.6 ± 4.9 40.5 ± 6.1 38.6 ± 5.7
Diff & 95% CI 0.6 (-0.78–1.95) 0.3 (-0.74–1.38) 1.2 (0.42–1.99)
WBC [103/μl] Evening 8.06 ± 2.00 8.01 ± 2.30 8.61 ± 2,00
Morning 7.20 ± 1.91 7.26 ± 2.23 7.67 ± 2.92
Diff & 95% CI 0.86 (0.86–1.18) 0.75 (0.75–1.29) 0.94 (0.46–1.65)
PMNs+monocytes [103/μl] Evening 5.68 ± 1.67 5.75 ± 2.00 5.50 ± 2.26
Morning 5.13 ± 1.63 5.19 ± 1.82 4.67 ± 1.45
Diff & 95% CI 0.55 (0.32–0.80) 0.56 (0.15–0.98) 0.83 (0.31–1.36)
Data expressed as a mean ± SD (standard deviation)
WBC – white blood cells, PMNs – polymorphonuclear leukocytes, 95% CI – 95% confidence interval, Diff – difference of means with 95% 
confidence intervalJournal of Negative Results in BioMedicine 2008, 7:10 http://www.jnrbm.com/content/7/1/10
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OSAS, as well as the control groups. FRAP reflects the sum
of antioxidant activities in various compounds [20]. They
may encompass dissimilar potentials in reducing Fe3+
ions, thereby varying along with the time of sample incu-
bation in their contribution to FRAP. Therefore, we addi-
tionally analyzed the effect of apneas-induced IH events
on FRAP obtained after various times of incubation. Fig-
ure 1 shows the mean evening and morning FRAP of
OSAS patients obtained after plasma sample incubation
from 0 till 8 min. No significant differences between the
evening and morning FRAP values were evident in each of
the times during incubation. Similar results were obtained
in CPAP-OSAS subjects, control group and the subgroup
of severe OSAS patients (data not shown). In vitro experi-
ments revealed that the incubation of plasma with H2O2
at concentrations: 47 μM and 16.5 mM for 1 hour did not
suppress FRAP (data not shown). Even H2O2 at a concen-
tration of 82.5 mM did not significantly decrease FRAP
(587 ± 12 μM vs. 603 ± 16 μM, n = 5, p > 0.05).
H2O2 activity in the whole blood
Only eight OSAS patients had detectable H2O2 levels in
the whole blood in the evening, while seven OSAS
patients observed detectable H2O2 post awakening. In the
whole OSAS group, evening H2O2 – 0.23 ± 0.44 μM (0;
0.30) did not differ (p > 0.05, n = 27) from the morning
– 0.22 ± 0.61 μM (0; 0.40) (95% CI -0.12 – 0.13). In the
subgroup of patients with severe OSAS, the ratio of posi-
tive H2O2 readings were 4/11 and 2/11 for the evening
and morning measurements. For CPAP-OSAS and the
control group, the ratio of H2O2 positive results were 4/22
and 3/11 for both evening and morning blood samples,
respectively. Similar to the whole group of OSAS patients,
no differences were found between the morning and
evening H2O2 activities in the remaining two groups as
well as in the subgroup of patients with severe OSAS (data
not shown). Furthermore, no differences manifested
among all three groups (data not shown).
Discussion
Parameters of resting and fMLP-induced LBCL were the
co-primary variables in our study. The morning and
Table 5: Luminol enhanced whole blood chemiluminescence (LBCL) measured before and after polysomnography controlled sleep
Patients undergoing polysomnography
Chemiluminescence parameter Time of the day OSAS Severe OSAS CPAP-OSAS Controls
rCL [aU/104p] Evening 2.4 ± 2.2 1.9 ± 1.8 2.2 ± 1.9 1.9 ± 1.8
Morning 2.3 ± 2.2 2.5 ± 2.8 1.5 ± 0.9 1.6 ± 1.5
Diff and 95% CI 0.1 (-0.7 – 0.8) 0.6 (0.15 – 1.02) 0.7 (0.1 – 1.2) 0.2 (-0.1 – 0.5)
pCL [aU/104p] Evening 6.4 ± 5.1 4.9 ± 4.7 6.0 ± 4.4 5.5 ± 4.3
Morning 5.9 ± 4.6 5.9 ± 4.8 4.3 ± 2.9 4.7 ± 2.5
Diff and 95% CI 0.5 (-0.9 – 1.8) 0,9 (-0.4 – 2.2) 1.6 (0.4 – 2.9) 5.2 (-2,0 – 12.4)
tCL [aU·s/104p] Evening 1939 ± 1532 1503 ± 1391 1805 ± 1278 1642 ± 1316
Morning 1790 ± 1371 1778 ± 1442 1313 ± 820 1416 ± 961
Diff and 95% CI 149 (-275 – 573) 275 (-117 – 668) 492 (132 – 852) 225 (22 – 430)
Peak time [s] Evening 281 ± 31 276 ± 37 293 ± 30 270 ± 24
Morning 275 ± 30 277 ± 37 284 ± 22 339 ± 23
Diff and 95% CI 6 (0.3 – 11.5) 1 (-5.3 – 6.5) 9 (0.1 – 16.3) 69 (-22 – 160)
rCl – the average resting chemiluminescence prior to addition of fMLP; pCL – maximal chemiluminescence signal after addition of fMLP; tCl – total 
light emission after cell stimulation with fMLP; peak time – the time from fMLP addition to the appearance of pCL; OSAS – patients with the 
untreated OSAS; Severe OSAS – patients with AHI ≥ 30; CPAP-OSAS – patients with OSAS treated successfully after a first attempt with CPAP, 
controls – subjects without OSAS Results expressed as mean ± SD, difference of means with 95% confidence interval (Diff and 95% CI) No 
significant differences (p > 0.05) were found for evening and morning LBCL parameters within and between the studied groups.Journal of Negative Results in BioMedicine 2008, 7:10 http://www.jnrbm.com/content/7/1/10
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evening chemiluminescence parameters like rCL, pCL and
tCL as well as FRAP were higher in OSAS patients in com-
parison with controls. Nevertheless, we did not find any
differences between morning and evening LBCL parame-
ters between and within the groups of OSAS, CPAP-OSAS
and the matched controls. Moreover, LBCL did not rise
significantly after polysomnography controlled sleep in
the subgroup of patients with severe untreated OSAS.
Therefore, our results suggest that OSAS related IH did not
enhance ROS production by blood PMNs and monocytes.
This finding is in contrast with the results of two previous
studies showing increased ROS production from isolated
PMNs (following stimulation with fMLP) and some sub-
populations of whole blood monocytes (resting and
phorbol myristate acetate – activated) of OSAS patients
[14,15].
Apart from the absence of cell isolation procedures and
the usage of monoclonal antibodies to surface cell mark-
ers possibly altering PMNs and monocytic responsiveness
to agonist stimulation, there were other significant differ-
ences between the protocols of our study and the afore-
mentioned. In previous studies, the control subjects were
not matched to OSAS patients in respect to age, BMI, cig-
arette smoking habits in addition to comorbidity [14,15].
Moreover, both investigations did not provide informa-
tion concerning concomitant pharmacologic treatment
[14,15]; furthermore, experiments on the effect of OSAS
related IH on monocytic activity were based on only 8 to
10 subjects out of the 18 enrolled [15] devoid of an unam-
biguous selective criterion.
In view of the fact that the majority of OSAS patients are
obese often developing a variety of cardiovascular and
metabolic diseases [1,2], there exists a challenge in find-
ing appropriate control subjects, chiefly in respects to
comorbidity and concomitant pharmacological treat-
ment. In our study, we overcome this impediment by
measuring LBCL prior to and following polysomno-
graphic controlled sleep, formulating comparisons within
and between study groups. These approaches act to possi-
bly eliminate biases related to patient medication, inten-
Ferric reducing ability of plasma (FRAP) before and after polisomnography controlled sleep Figure 1
Ferric reducing ability of plasma (FRAP) before and after polisomnography controlled sleep. Closed circles – 
evening (before polisomnography controlled sleep). Open circles – morning (after polisomnography controlled sleep). Results 
of FRAP in 27 subjects with OSAS expressed as mean and standard deviations represent the concentration of Fe3+ reduced 
ions after 0, 1, 2, 3, 4, 5, 6, 7 and 8 min incubation of patient plasma sample with the FRAP reagent. No significant differences (p 
> 0.05) were found for evening and morning FRAP at all incubation time-points.Journal of Negative Results in BioMedicine 2008, 7:10 http://www.jnrbm.com/content/7/1/10
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sifying the quality of our results in showing no priming or
activation of blood phagocytes in untreated OSAS
patients.
The sympathetic over activity in OSAS patients resulting in
the rise of plasma norepinephrine and epinephrine levels
[25-27] may perhaps be responsible in the insignificant
changes between evening and morning blood LBCL in
OSAS patients. Reports have demonstrated a higher morn-
ing (following awakening) plasma norepinephrine con-
centration than those before sleep in OSAS patients by
24% [25]. Nonetheless, a night of successful CPAP ther-
apy resulted in a down-regulation of sympathetic activity
as well as a decrease in circulating catecholamines by 20%
[26]. Catecholamines in vitro, especially epinephrine at
physiologic levels revealed concentration dependent inhi-
bition of fMLP-induced degranulation and superoxide
radical production by human PMNs [28-30]; with a capa-
bility of suppressive monocytic activity as well [31,32].
Therefore, exposition of circulating phagocytes to
increased concentrations of catecholamines may result in
their insusceptibility to the priming effect of IH in respira-
tory burst, assuming responsibility for the negative results
in untreated OSAS patients. On the other hand, the obser-
vation of rapidly reversible sympathetic over-activation
due to successful treatment [26] elucidates the indiffer-
ences among morning and evening LBCL in CPAP-OSAS
group. This may result from the simultaneous reduction
of IH episodes along with plasma catecholamine suppres-
sion, together with a rapid turnover of circulating PMNs;
strongly supported by a recent study demonstrating the
inhibitory effect of exercise on hypobaric hypoxia-
induced enhancement of ROS production by PMNs in
healthy volunteers [33]. It cannot be excluded that our
OSAS patients encountered an inadequate amount of
apneas/hypopneas, consequently observing insufficient
blood desaturations to prime PMNs to fMLP stimulation.
In the abovementioned study, overnight hypobaric
hypoxia decreased the average SaO2 from a baseline of
98% to 93% concluding a high altitude stay [33].
A decreased average SaO2 (84%) along with minimal
SaO2 (68%) was evident in our investigated patients, par-
ticularly those with severe OSAS, due to numerous tran-
sient desaturations. The activity of two secondary
variables (FRAP and H2O2 activity in the whole blood) in
OSAS patients after sleep was compatible to the results of
LBCL. We did not observe sleep-induced ROS overproduc-
tion in the blood (LBCL, H2O2 activity) of untreated OSAS
patients, therefore no suppression of morning FRAP was
noted. On the other hand, resistance of FRAP to 1 h in
vitro incubation with high concentrations of H2O2 sug-
gests strong antioxidant plasma capacity. Therefore, FRAP
suppression related to significant expenditure of circulat-
ing antioxidants with high Fe3+ reducing activity will occur
in vivo in the case of large and long (probably longer than
one night) systemic ROS overproduction.
The results of our study suggest that circulating phago-
cytes (PMNs and monocytes) are not the main culprit of
OSAS consequences in the human body. It does not
exclude augmented ROS production and activation of the
systemic ROS signaling [7,14,34]. Circulating phagocytes
probably do not take part in oxidative stress, which does
not synonymously reject the oxidative stress presence in
OSAS patients. It can take place near or exactly in blood
vessel endothelium, which can significantly accelerate
atherosclerosis.
Conclusion
In conclusion, untreated OSAS patients did not present
with elevated resting and fMLP induced LBCL when com-
pared with age-, BMI-, and smoking habits- matched con-
trols. Moreover, no significant alterations of evening vs.
morning LBCL, blood H2O2  activities and FRAP were
noted in OSAS patients. These indicate that circulating
PMNs and monocytes did not produce increased amounts
of ROS and did not contribute to oxidative stress in OSAS
patients.
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